EGFR and esophageal squamous cell carcinoma: The recognition of miR-548k in regulating lymphangiogenesis and lymphatic remodelling are functionally important in ESCC progression, which led to the idea that miR-548k might be employed as a new diagnostic and prognostic marker and a predictive marker for anti-VEGFC or anti-EGFR therapy strategies in ESCC treatment, or even served as a therapeutic target synergizing with anti-VEGFC or anti-EGFR therapies.